ZNF800 is a zinc finger transcription factor with dual roles in cell fate determination and cancer progression. Primary Function: ZNF800 acts as a master repressor of enteroendocrine cell differentiation, particularly restricting enterochromaffin cell commitment by directly controlling the endocrine transcription factor PAX4 1. The protein functions as a DNA-binding transcription repressor with activity specific to RNA polymerase II [GO annotations]. Mechanism: ZNF800 operates as a trans-eQTL master regulator affecting adipose gene expression networks 2. In colorectal cancer, circular RNA ZNF800 functions as a competing endogenous RNA, sponging miRNAs (miR-140-3p, miR-382-5p, miR-579-3p) to promote cancer stem cell properties 3. In lung cancer, miR-140-5p negatively regulates ZNF800 to suppress proliferation and metastasis 4. Disease Relevance: Elevated ZNF800 expression correlates with poor prognosis in lower-grade gliomas, promoting tumor cell proliferation and migration while associating with immune checkpoint molecule expression 5. ZNF800 is identified as a key mediator in IAPP-induced beta cell injury relevant to type 2 diabetes pathogenesis 6. Single-variant associations link ZNF800 to cataract susceptibility 7. Clinical Significance: ZNF800 serves as a biomarker for cancer diagnosis and prognosis and represents a potential therapeutic target for combination immunotherapy and cancer stem cell-directed interventions.